Pharma BD Deal Intelligence
DSP to acquire Boston Biomedical, gaining first-in-class cancer stemness inhibitors BBI608 and BBI503; the acquisition establishes a foundation for DSP's…
GEN reported the BRIGHTER Phase 3 gastric cancer failure, calling the readout a 'disappointment' that further eroded confidence in the cancer-stemness platform…
Prior setbacks have raised doubts about the prospects of some of the assets, as Sumitomo merges its U.S. biotechs into a single oncology division years after…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Dainippon Sumitomo acquired Boston Biomedical for $200M upfront plus up to $540M in development milestones and $1.89B in commercial milestones (~$2.63B total). Acquired cancer stem cell-targeting oncology pipeline (BBI608 entering Phase 3 CRC; BBI503 Phase 1 solid tumors).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc. (this deal) | 2012 | $2.6B | 24 |
| Dainippon Sumitomo Pharma Co., Ltd. / Sepracor Inc. | 2009 | $2.6B | 63 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2012 deals · Oncology deals